TY - JOUR
T1 - Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer
T2 - A phase 2 trial
AU - Dipetrillo, Thomas
AU - Suntharalingam, Mohan
AU - Ng, Thomas
AU - Fontaine, Jacques
AU - Horiba, Naomi
AU - Oldenburg, Nicklas
AU - Perez, Kimberly
AU - Birnbaum, Ari
AU - Battafarano, Richard
AU - Burrows, Whitney
AU - Safran, Howard
PY - 2012/2
Y1 - 2012/2
N2 - PURPOSE: To evaluate the pathologic complete response (CR) rate and safety of paclitaxel poliglumex (PPX), cisplatin, and concurrent radiation for patients with esophageal cancer. PATIENTS AND METHODS: Patients with adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction with no evidence of distant metastasis received PPX (50 mg/m/wk) and cisplatin (25 mg/m/wk) for 6 weeks with 50.4 Gy concurrent radiation. Six to eight weeks after completion of chemoradiotherapy, patients underwent surgical resection. RESULTS: Forty patients were enrolled, 37 patients with adenocarcinoma and 3 patients with squamous cell cancer. The treatment-related grade 3 nonhematologic toxicities included esophagitis (7%), nausea (7%), and fatigue (5%). Three patients with clinical endoscopic CR (2 with squamous cell cancer) refused surgery. Twelve of the remaining 37 patients (32%) had a pathologic CR. The 12 patients with pathologic CR all had adenocarcinoma. CONCLUSION: PPX, cisplatin, and concurrent radiation are well tolerated, easily administered regimen for esophageal cancer with a low incidence of significant esophagitis and a high pathologic CR rate consistent with the preclinical data of PPX and radiation.
AB - PURPOSE: To evaluate the pathologic complete response (CR) rate and safety of paclitaxel poliglumex (PPX), cisplatin, and concurrent radiation for patients with esophageal cancer. PATIENTS AND METHODS: Patients with adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction with no evidence of distant metastasis received PPX (50 mg/m/wk) and cisplatin (25 mg/m/wk) for 6 weeks with 50.4 Gy concurrent radiation. Six to eight weeks after completion of chemoradiotherapy, patients underwent surgical resection. RESULTS: Forty patients were enrolled, 37 patients with adenocarcinoma and 3 patients with squamous cell cancer. The treatment-related grade 3 nonhematologic toxicities included esophagitis (7%), nausea (7%), and fatigue (5%). Three patients with clinical endoscopic CR (2 with squamous cell cancer) refused surgery. Twelve of the remaining 37 patients (32%) had a pathologic CR. The 12 patients with pathologic CR all had adenocarcinoma. CONCLUSION: PPX, cisplatin, and concurrent radiation are well tolerated, easily administered regimen for esophageal cancer with a low incidence of significant esophagitis and a high pathologic CR rate consistent with the preclinical data of PPX and radiation.
KW - esophageal cancer
KW - paclitaxel poliglumex
KW - radiation
UR - http://www.scopus.com/inward/record.url?scp=84856236634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856236634&partnerID=8YFLogxK
U2 - 10.1097/COC.0b013e318201a126
DO - 10.1097/COC.0b013e318201a126
M3 - Article
C2 - 21297434
AN - SCOPUS:84856236634
SN - 0277-3732
VL - 35
SP - 64
EP - 67
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 1
ER -